NewTimeSpace (newtimespace.com) News, on August 26, 2026, the chip theme strengthened, with ASMPT (00522.HK) rising in choppy trade. As of 13:28, the stock was quoted at HKD 167.100, up 2.83%.
NewTimeSpace (newtimespace.com) News, on August 26, 2026, the robotics theme fluctuated intraday, with XIAOMI-W (01810.HK) strengthening. As of 13:12, the stock was quoted at HKD 28.780, up 3.67%.
NewTimeSpace News: GenFleet Therapeutics announced on August 26 that GFH375, an oral KRAS G12D inhibitor, has entered Phase‑II clinical development for first‑line treatment of advanced KRAS‑G12D‑mutant non‑small‑cell lung cancer (NSCLC). Three regimens are being investigated: monotherapy, combination with anti‑EGFR monoclonal antibody, and combination with chemotherapy.
NewTimeSpace News: Akesobio announced on August 26 that its self‑developed Ivonescimab (PD‑1/VEGF) in combination with chemotherapy met the primary overall‑survival endpoint in the Phase III trial versus dostarlimab plus chemotherapy for first‑line treatment of advanced biliary tract cancer, delivering positive results with statistically significant and clinically meaningful benefits.
NewTimeSpace News: On 25 August 2026, CSPC PHARMA (01093.HK) announced that its recombinant respiratory syncytial virus vaccine (SYS6057) has been approved by the US FDA to conduct clinical trials, following the NMPA approval on 30 July 2026; the product is the Group's second recombinant protein vaccine, with the approved indication of preventing RSV-associated lower respiratory tract disease (LRTD) in people aged 60 and above.
NewTimeSpace News: On 24 August 2026, IMMUNEONCO-B (01541.HK) announced that its self-developed ActRIIA-Fc fusion protein IMC-003 has achieved two clinical milestones: the first patient has been enrolled and dosed in the Phase Ib/IIa PAH trial; the SAD study has completed enrollment and safety observation of all seven dose cohorts with good tolerance at 8 mg/kg and no DLT, while the MAD study has completed enrollment of all dose cohorts (the fourth cohort of eight subjects completed enrollment on 17 August 2026).
On August 25, 2026, The Hang Seng Index (HSI) edged down 0.02%, the Hang Seng TECH Index edged down 0.12%, and the Hang Seng China Enterprises Index fell 0.31%.The AI chip segment strengthened across the board, with MONTAGE TECHNOLOGY (06809.HK) up 4.96%, GIGADEVICE (03986.HK) up 4.93%, and BIREN TECH, ILUVATAR COREX, SMIC, and HUA HONG GRACE following the gains.
NewTimeSpace News: On 25 August 2026, SSY GROUP (02005.HK) announced that it has obtained production registration approvals for sodium ozagrel injection (5ml:40mg and 2.5ml:20mg), classified as chemical drug Category 3 and deemed to have passed the consistency evaluation, for the treatment of acute thrombotic cerebral infarction and accompanying movement disorders; together with the two existing large-volume infusion specifications, the approval achieves full dosage form coverage of the product, helping to expand into the neurology market.
NewTimeSpace News: On August 25, 2026, RoboSense (02498.HK) trended stronger in the afternoon session. As of 14:54, the stock traded at HK$18.62, representing an increase of 4.02%.
NewTimeSpace (newtimespace.com) News, on August 25, 2026, the chip theme rose amid volatility, and SMIC (00981.HK) strengthened. As of 13:39, the company's quote stood at HKD 68.200, up 2.17%.
NewTimeSpace (newtimespace.com) News, on August 25, 2026, the robot theme strengthened amid volatility, and UBTECH ROBOTICS (09880.HK) rallied in the midday session. As of 13:16, the company's quote stood at HKD 81.300, up 2.07%.
NewTimeSpace News: Hengrui Pharmaceuticals released an overseas regulatory announcement on August 24. The New Drug Application for HRG2010 Capsules has been accepted by the National Medical Products Administration, with the proposed indication for Parkinson’s disease.
NewTimeSpace News: Antengene Corporation announced on August 25 that ATG‑201, its self‑developed CD19/CD3 bispecific T‑cell engager antibody for B‑cell‑related autoimmune diseases, has obtained approval from Australia’s Human Research Ethics Committee for its Phase I ATTRACT study.
NewTimeSpace News: On 24 August 2026, CF PHARMTECH (02652.HK) announced that its self-developed long-acting inhaled dry powder drug candidate ICF001 has obtained implied approval from the NMPA to conduct clinical trials for IPF and PPF, expanding its indications to four following the earlier approvals for PAH and PH-ILD; the Company plans to conduct Phase I clinical trials in China and explore global multi-center development and cooperation opportunities.
NewTimeSpace News: On 24 August 2026, BAO PHARMA-B (02659.HK) announced that the FDA has approved the IND application for its self-developed KJ015 injection, an anti-HER2 bispecific antibody subcutaneous formulation, permitting clinical trials in the United States; KJ015 previously received IND approval from the National Medical Products Administration in December 2024, with Phase I clinical trials in China commenced in June 2025 and expected to be completed in the second half of 2026.
On August 24, 2026, the technology theme pulled back sharply, and AI concept stocks weakened across the board today. The Hang Seng Index fell 1.89%, the Hang Seng TECH Index dropped 3.61%, and the Hang Seng China Enterprises Index fell 1.89%. The Hang Seng Index's full-day total market turnover was HKD 291.2 billion, with southbound funds recording a net inflow of HKD 11.567 billion.The smart-driving segment was mixed: WERIDE-W (00800.HK) rose 1.54% against the trend, ROBOSENSE (02498.HK) fell 14.52%, and HORIZONROBOT-W, BLACK SESAME, and PONY-W followed lower.
